4.5 Article

ILAE classification of the epilepsies: Position paper of the ILAE Commission for Classification and Terminology

Journal

EPILEPSIA
Volume 58, Issue 4, Pages 512-521

Publisher

WILEY
DOI: 10.1111/epi.13709

Keywords

Classification; Epilepsy syndromes; Terminology; Etiology

Funding

  1. UCB
  2. Eisai
  3. Athena Diagnostics
  4. GlaxoSmithKline
  5. Transgenomics
  6. Biocodex
  7. National Health and Medical Research Council
  8. Australian Research Council
  9. National Institutes of Health (NIH)
  10. Human Research Council
  11. Citizens United for Research in Epilepsy (CURE)
  12. US Department of Defense
  13. March of Dimes
  14. UCB Pharma
  15. Novartis Pharmaceuticals
  16. Sanofi-Aventis
  17. Novartis
  18. Sage Therapeutics
  19. CIHR (Canadian Institute for Health Research)
  20. Alva Foundation
  21. Acorda
  22. Alexza
  23. LCGH
  24. Eisai Medical Research
  25. Lundbeck
  26. Pfizer
  27. SK Life Sciences
  28. Upsher-Smith
  29. Vertex
  30. National Institute of Neurological Disorders and Stroke
  31. Epilepsy Therapy Project
  32. Epilepsy Research Foundation
  33. Epilepsy Study Consortium
  34. Associate Editor of Epilepsia
  35. Bial
  36. Davies/Crandall Chair for Epilepsy Research at UCLA
  37. NIH [NS43209, 1U54NS100064-01, 1-RO1-NS43209]
  38. CURE Infantile Spasms Initiative
  39. US Department of Defense [W81XWH-13-1-0180]
  40. Heffer Family Foundation
  41. Segal Family Foundation
  42. Abbe Goldstein family
  43. Joshua Lurie family
  44. Laurie Marsh family
  45. Dan Levitz family
  46. CURE
  47. Biopharm Solutions
  48. GW Pharma
  49. Mylan
  50. Sanofi
  51. Sun Pharma
  52. Takeda
  53. Stockholm County Council
  54. EU
  55. Electrocore
  56. Sunovion
  57. Epilepsy Research UK
  58. Dravet Syndrome UK

Ask authors/readers for more resources

The International League Against Epilepsy (ILAE) Classification of the Epilepsies has been updated to reflect our gain in understanding of the epilepsies and their underlying mechanisms following the major scientific advances that have taken place since the last ratified classification in 1989. As a critical tool for the practicing clinician, epilepsy classification must be relevant and dynamic to changes in thinking, yet robust and translatable to all areas of the globe. Its primary purpose is for diagnosis of patients, but it is also critical for epilepsy research, development of antiepileptic therapies, and communication around the world. The new classification originates from a draft document submitted for public comments in 2013, which was revised to incorporate extensive feedback from the international epilepsy community over several rounds of consultation. It presents three levels, starting with seizure type, where it assumes that the patient is having epileptic seizures as defined by the new 2017 ILAE Seizure Classification. After diagnosis of the seizure type, the next step is diagnosis of epilepsy type, including focal epilepsy, generalized epilepsy, combined generalized, and focal epilepsy, and also an unknown epilepsy group. The third level is that of epilepsy syndrome, where a specific syndromic diagnosis can be made. The new classification incorporates etiology along each stage, emphasizing the need to consider etiology at each step of diagnosis, as it often carries significant treatment implications. Etiology is broken into six subgroups, selected because of their potential therapeutic consequences. New terminology is introduced such as developmental and epileptic encephalopathy. The term benign is replaced by the terms self-limited and pharmacoresponsive, to be used where appropriate. It is hoped that this new framework will assist in improving epilepsy care and research in the 21st century.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available